Lotus sets sights on building powerful regional health care platform
Pharmaceutical company specialises in difficult-to-develop generic medication to address central nervous system diseases and other concerns in the fields of oncology, cardiology and nephrology
Country Business Reports interviews and articles by Discovery Reports www.discoveryreports.com
When next-generation pharmaceuticals company Alvogen was on the lookout for potential acquisitions to strengthen its Asian business, Lotus Pharmaceuticals emerged as the clear choice. Its expertise in speciality generic medicine and strict compliance to international standards positioned Lotus as an ideal company to help Alvogen in achieving its vision of being among the top 10 global generic pharmaceutical companies.
“Medical institutions tend to use imported products, but Lotus is one of the few trusted go-to companies by hospitals. Alvogen wanted a company which is strong in the hospital sector and Lotus has that advantage,” says CEO and general manager Siegfried Gschliesser.
Lotus specialises in difficult-to-develop generic medication to address central nervous system diseases and other concerns in the fields of oncology, cardiology and nephrology. The company complies with the rigorous standards of a highly regulated industry. Its certifications from the United States Food and Drug Administration, European Medicines Agency, China Food and Drug Administration, Japan’s Pharmaceuticals and Medical Devices Agency and Taiwan Food and Drug Administration are a testament to the level of quality to which Lotus adheres. Its strong commitment opens up more opportunities in those advanced markets and builds a solid foundation to become a global leader.
Contributing to creating better access to quality health care globally, Lotus manufactures high-quality medicine at affordable prices. Furthermore, it welcomes collaborations with other pharmaceutical companies to shorten time-to-market – something that is crucial especially in time-sensitive health issues.
“We see many opportunities for manufacturers that do not have market access like we have. They can develop and produce the medicine, and we can market it for them,” Gschliesser says.
With Lotus’ distributor network across Asia, other companies can access markets such as mainland China, Taiwan, Hong Kong, Thailand, Myanmar, South Korea, Singapore and the Philippines.
Lotus also has ample capacity to offer contract manufacturing and development services. The company possesses particular expertise in manufacturing tablets, capsules and soft gels. It also has dedicated facilities for cytotoxic and high-potency hormone drugs in various forms.
Backed by Alvogen’s expertise in biopharmaceuticals and biosimilars and the financial power of its investors, Lotus goes full steam ahead in the development of new medicine. European private equity firm CVC Capital Partners and Singaporean sovereign investment company Temasek are among a consortium of Alvogen investors.
“Lotus is a local high-growth company with concrete plans of becoming the pioneer regional player. We seek investors that push us closer to becoming the platform to offer health care and generic products across Asian markets,” Gschliesser says.